<DOC>
	<DOCNO>NCT00328198</DOCNO>
	<brief_summary>This Phase II , open-label , prospective , multicenter study evaluate efficacy safety subcutaneously administer alemtuzumab ( CAMPATH , MabCampath ) therapy patient relapse refractory B-CLL previously treat .</brief_summary>
	<brief_title>Subcutaneous Alemtuzumab ( CAMPATH® , MabCampath® ) Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>A diagnosis Bcell chronic lymphocytic leukemia ( BCLL ) ; accord National Cancer Institute Working Group ( NCI WG ) Criteria . World Health Organization ( WHO ) performance status 0 , 1 , 2 . Life expectancy ≥ 12 week . Previous therapy least one 5 regimen ( single agent combination regimen ) . One therapy regimen define consecutive , contiguous cycle drug ( ) treatment interruption last &gt; 3 month . Patient require treatment CLL per follow criterion : Rai stage III IV ; Rai stage 0II least one follow evidence progressive marrow failure manifest development , worsen , anemia and/or thrombocytopenia ; Massive ( i.e . great 6 cm leave costal margin ) progressive splenomegaly ; Progressive lymphocytosis increase great 50 % 2month period anticipate doubling time le 6 month ; Lymphocyte count &gt; 100*10^9/L ; B symptom . More 3 week since prior chemotherapy . Patient must recover acute side effect incur result previous therapy . More 3 week since use investigational agent . Patient must recover acute side effect incur result previous therapy . Serum creatinine conjugate ( direct ) bilirubin less equal 2 time institutional upper limit normal ( ULN ) unless secondary direct infiltration liver CLL . Female patient childbearing potential must negative pregnancy test ( serum urine ) within 2 week first dose study drug ( ) . All patient must agree use effective contraceptive method study treatment , appropriate , minimum 6 month follow study therapy . Signed , write informed consent ( US , include The Health Insurance Portability Accountability Act 1996 ( HIPAA ) authorization ) Positive Coombs test evidence active hemolysis . Platelet count le 50*10^9/L without splenomegaly . History anaphylaxis follow exposure rat mouse derive CDRgrafted humanize monoclonal antibody . Previously treat CAMPATH . Previous bone marrow transplant . Known central nervous system ( CNS ) involvement BCLL Active infection , include human immunodeficiency virus ( HIV ) positive . Active second malignancy . Recent documented history ( within 2 year ) active tuberculosis ( TB ) , current active TB infection , currently receive antituberculous medication ( e.g. , INH , rifampin , streptomycin , pyrazinamide , others ) . Active hepatitis history prior viral hepatitis B hepatitis C , positive hepatitis B serology . Patients positive hepatitis B surface antibody ( HBsAb ) test document history prior hepatitis B immunization eligible long criterion meet ( i.e . negative test : hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody ( HBcAb ) hepatitis C virus antibody ( HCVAb ) ) . Other severe , concurrent disease ( e.g. , cardiac pulmonary disease ) , mental disorder , major organ malfunction ( liver , kidney ) could interfere patient ability participate study . Pregnant nursing woman . Cytomegalovirus ( CMV ) positive polymerase chain reaction ( PCR ) ( level detection ) . A patient PCR positive require treatment reduce viral load nondetectable level ; patient may consider study entry infection treat . Medical condition require chronic use oral corticosteroid dose high physiologic replacement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>CAMPATH</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Leukemia</keyword>
	<keyword>MabCampath</keyword>
	<keyword>Chronic</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>CLL</keyword>
	<keyword>C-CLL</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
</DOC>